

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner For Patents, P.O. Box 1450. Alexandria, VA 22313-1450 on

John M. Howell 33,713
Name of Aftorney or Agent Registration

Signature of Attorney or Agent

Group Art Unit 1616

P&G Case CM2727C

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of

Serial No. 10/781,457

approduction of

A. Brooks et al. : Confirmation No. 1750

Filed February 18, 2004 : Examiner

For Film-forming Compositions for Topical Application

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents

P. O. Box 1450

Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, record is being made on the attached Form PTO/SB08 of documents which the Patent Office may wish to consider in connection with examination of the above-identified patent application. It is respectfully requested that the cited documents be carefully considered by the Examiner and made of record in this case. As provided in §1.97(g), no representation is made or intended that a thorough art search was made. As provided in 37 C.F.R. §1.97(h), this Supplemental Information Disclosure Statement does not constitute an admission of any kind, and specifically is not an admission that the documents listed on attached form PTO/SB08 are, or are considered to be, material to the patentability of the above-identified patent application, as defined in 37 C.F.R. §1.56(b).

1. [] 37 C.F.R. §1.97(b)(1) - U.S. Direct (use when filing IDS with nonprovisional patent application, or with Request for Continued Examination (RCE); or within 3 months of filing a nonprovisional patent application)

This information disclosure statement, submitted under 37 C.F.R. §1.97(b)(1), is being filed with the patent application, with a Request for Continued Examination or within three months of the filing date of a national application. Therefore, no fee is believed to be due.

2. [X] <u>37 C.F.R. §1.97(b)(3)</u> - (use when filing IDS more than 3 months after filing a nonprovisional patent application, but prior to receipt of first Office Action)

This information disclosure statement is being submitted under 37 C.F.R. §1.97(b)(3). Applicants have not received an Office Action on the merits in the present application. Therefore, no fee is believed to be due. However, in the event that this paper is crossing in the mail with a first Office Action on the merits, authorization is hereby given to charge the required fee pursuant to 37 C.F.R. §1.97(c) and 37 C.F.R. §1.17(p) to Deposit Account No. 16-2480 in the name of The Procter & Gamble Company. A duplicate of this letter (or a fee transmittal form) is enclosed to facilitate charging of the fee, if necessary.

3. [] 37 C.F.R. §1.97(b)(4) - (use when filing IDS prior to receipt of first Office Action after the filing of a Request for Continued Examination (RCE) under §1.114)

This information disclosure statement is being submitted under 37 C.F.R. §1.97(b)(4). Applicants have not received a first Office Action after filing a Request For Continued Examination (RCE). Therefore, no fee is believed to be due. However, in the event that this paper is crossing in the mail with a first Office Action on the merits, authorization is hereby given to charge the required fee pursuant to 37 C.F.R. §1.97(c) and 37 C.F.R. §1.17(p) to Deposit Account No. 16-2480 in the name of The Procter & Gamble Company. A duplicate of this letter (or a fee transmittal form) is enclosed to facilitate charging of the fee, if necessary.

4. [] <u>37 C.F.R. §1.97(c)</u> with fee payment - (use when filing IDS after receipt of first Office Action, and before receipt of Final Office Action, Notice of Allowance, or an action that otherwise closes prosecution)

This information disclosure statement is being submitted under 37 C.F.R. §1.97(c). Applicant(s) have not received a final action under 37 C.F.R. §1.113, a notice of allowance under 37 C.F.R. §1.311, or an action that otherwise closes prosecution in the application (e.g., *Ex parte Quayle*) as of the date of this submission. Applicant(s) elect to pay the fee set forth in 37 C.F.R. §1.17(p). Please charge the fee set forth in 37 C.F.R. §1.17(p) to Deposit Account Number 16-2480 in the name of The Procter & Gamble Company. A duplicate copy of this letter (or a fee transmittal form) is enclosed to facilitate the charging of the fee.

5. [] <u>Information to be Considered with Continued Prosecution Application (CPA)</u> <u>Filing (use when filing IDS with a Continued Prosecution Application (CPA) for Design Case)</u>. This information disclosure statement is being filed with a Continued Prosecution Application (CPA) filed under 37 C.F.R. 1.53(d).

ADDITIONAL ITEMS TO BE NOTED BY THE EXAMINER:

[X]	(1) In accordance with 37 C.F.R. §1.98(a)(2), Applicants are submitting copies of
foreign pate	nt documents and non-patent literature.
	OR
[] (2)	All of the cited references were previously cited by or submitted to the USPTO in prior
application	Case No, U.S. Patent Application Serial No, filed Applicants claim priority
to said appl	ication under 35 U.S.C. §120. Accordingly, copies of previously submitted references
are not prov	rided with this Statement, pursuant to 37 C.F.R. §1.98(d). It is respectfully requested that
the cited do	cuments be carefully considered by the Examiner and made of record in this case.
	OR
[] (3)	Copies of all said documents, except Cite Numbers, were submitted and
considered	in parent application U.S. Patent Application Serial No, filed
Applicant(s)	claim priority to said application under 35 U.S.C. §120. Accordingly, copies of
previously s	submitted references are not provided with this Statement, pursuant to 37 C.F.R. §1.98(d).
_	eferences not previously submitted are enclosed. It is respectfully requested that the cited
documents l	be carefully considered by the Examiner and made of record in this case.
ГЭ	
(4)	Pursuant to 37 C.F.R. §1.98(c), a concise explanation of the relevance of each cited
reference th	at is not in the English language is provided.
רז	
(5)	Applicants also respectfully request the Examiner to consider and make of record the
co-pending	applications listed on the attached page.
LJ	
IJ	Additional information is attached.
	Respectfully submitted,
	By John W Hausell
	John M. Howell
	Attorney for Applicants Registration No. 33,713
A.	7 7 (513) 626-3792
1 ory	2/

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

CM2727C

Under the Paperwork Reduction Act of 1995, no persons are required to resp		ess it contains a valid OMB control number		
Substitute for form 1449A/PTO	COMPLETE IF KNOWN			
	Application Number	10/781,457		
INFORMATION DISCLOSURE	Confirmation Number	1750		
STATEMENT BY APPLICANT	Filing Date	02/18/2004		
(use as many sheet as necessary)	First Named Inventor	Alan Brooks		
	Group Art Unit	1616		
liii a n anoc ပိပါ	Examiner Name			

SHEET 1 of 1 Attorney Docket Number **U. S. PATENT DOCUMENTS**

	Cite	DOCUMENT NUMBER		T .	Pages, Columns, Lines Where	
	No.1	Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Relevant Passages or Relevant Figures Appear	
			<u> </u>			
					,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	
	1					

FOREIGN PATENT DOCUMENTS

		FOREIGN PATENT DOCUMENT				Pages, Columns, Lines	
EXAMINER INITIALS*	Cite No.1	Country Code ³ Number ⁴	Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	7 6
	01	EP 0 780 116 B1		06/25/1997	Shiseido Co., Ltd.		
	02	JP 09-095584 A		04/08/1997	Shiseido Co., Ltd.		Abstract
	03	WO 01/39730 A1		06/07/2001	Orion Corporation		

NON PATENT LITERATURE DOCUMENTS

EXAMINER INITIALS*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published				
	04	Derwent Publication XP002283611, #Accession No 1986-195002, Intr. Prod. Cosmetice Miraj (12/30/1985)				
	05	Derwent Publication XP002282930, #Accession No 1995-144670, Kao Corp. (03/14/1995)				
	06	Chemical Abstracts Service XP002282929, Accession No. 2000:452478, Kyowa Industrial Co., Ltd. (7/04/2000)				
, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,						
EXAMINE	₹	DATE CONSIDERED				

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional).

Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 37 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2

hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO-SB08 (Revised for P&G use 10/8/2003)